ASCRS warns about alpha-blockers

The American Society of Cataract and Refractive Surgery, the American Academy of Ophthalmology and the American Urological Association are again pressing a message that cataract surgeons say is often missed until too late: ask about alpha-blockers before the patient reaches the operating room. Coverage in *Ophthalmology Times* said the groups urged cataract patients to disclose medicines used for benign prostatic hyperplasia and lower urinary tract symptoms before surgery, citing retrospective and prospective evidence on intraoperative floppy iris syndrome, or IFIS. The warning is not new in substance. AAO and ASCRS have carried joint educational and patient-advisory materials on alpha-blockers and IFIS for years, and those materials say patients with cataracts should consider the surgical implications before starting an alpha-blocker prescription. ### Which drugs are at the center of the warning? Alpha-1 antagonists used for urinary symptoms are the main focus, with tamsulosin repeatedly cited in ophthalmology guidance as a drug associated with IFIS during cataract surgery. (ophthalmologytimes.com) The 2014 AAO-ASCRS patient advisory says alpha-blocker drugs can increase the difficulty of cataract surgery, while an AAO educational statement links systemic alpha-1 antagonists to sudden iris prolapse and pupil constriction during surgery. (aao.org) A more recent American Journal of Ophthalmology report described alpha-1 blockers as the drug class most strongly associated with IFIS in a real-world pharmacovigilance analysis, according to AAO and secondary coverage summarizing the study. ### Why does disclosure before surgery matter so much? IFIS is an intraoperative problem, but the societies’ message is aimed at preoperative workflow. *Ophthalmology Times* said the groups want medication review moved earlier so surgeons can anticipate small-pupil behavior and prepare strategies before the day of surgery. (aao.org) AAO educational material describes IFIS as billowing iris tissue, iris prolapse and progressive miosis during cataract surgery. (aao.org) An AAO video on the condition says proper history-taking and preoperative workup are critical to preventing related complications, including iris trauma and posterior capsular rupture. ### What changes in the pre-op routine are the societies pushing? The practical shift is toward explicit medication checks, not general questions about prescriptions. *Ophthalmology Times* said the advisory emphasizes alpha-blockers used for benign prostatic hyperplasia and lower urinary tract symptoms, signaling that surgeons and staff should ask directly about that drug class. (ophthalmologytimes.com) Earlier ASCRS-AAO outreach also targeted primary care physicians and other prescribers, saying doctors should consider involving the cataract surgeon when treating a patient with a known cataract who may start alpha-blocker therapy. (aao.org) That cross-specialty approach mirrors the current push for communication before the patient arrives for surgery. ### Does stopping the drug solve the problem? The available guidance is more cautious than a simple stop-order. (ophthalmologytimes.com) AAO and ASCRS materials focus primarily on identifying exposure and planning for surgery, rather than promising that discontinuation will remove the risk. A 2009 report summarized by *Ophthalmology Times Europe* found that recent tamsulosin exposure was associated with higher rates of serious postoperative ophthalmic adverse events, while AAO educational material says IFIS severity varies and surgeons may need staged management approaches. (ophthalmologytimes.com) ### What should clinicians and patients watch for next? The next step is procedural rather than regulatory. Joint AAO-ASCRS materials already exist for patients and surgeons, and the latest coverage points to the same operational change: build alpha-blocker screening into pre-op checklists and referral communication before cataract surgery is scheduled. (aao.org) (ophthalmologytimes.com) (europe.ophthalmologytimes.com)